Fig. 3

A patient-derived immune response signature predicts clinical outcome of PCV2 infection. a Diagram of cohort division between training and test set. A clinical PCV2 signature was calculated from the training samples and (b) tested in the validation samples by GSEA. The PCV2 disease signature was markedly induced in the validation set, and repressed in subclinical PCV2 29dpi. c Nearest Template Prediction of test set samples, classifying them either as healthy (blue) or PMWS (red), and (d) similarly, of the experimental subclinical infection samples at 29dpi. e–g Kinetics of the PCV2 disease signature upon experimental PCV2, S. Typhimurium and S. Choleraesuis infection